JMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix
Analyst Jonathan Wolleben from JMP Securities has reaffirmed Ocular Therapeutix (NASDAQ: OCUL) with a Market Outperform rating and a $24 ...
Analyst Jonathan Wolleben from JMP Securities has reaffirmed Ocular Therapeutix (NASDAQ: OCUL) with a Market Outperform rating and a $24 ...
Piper Sandler analyst Joseph Catanzaro has reiterated his positive outlook on Ocular Therapeutix (NASDAQ: OCUL) by maintaining an Overweight rating ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.